Functionally Deregulated AML1/RUNX1 Cooperates with BCR-ABL to Induce a Blastic Phase-Like Phenotype of Chronic Myelogenous Leukemia in Mice

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Yamamoto, Kiyoko ^a,b   Tsuzuki, Shinobu ^a   Minami, Yosuke ^b   Yamamoto, Yukiya ^c   Abe, Akihiro ^c   Ohshima, Koichi ^d   Seto, Masao ^a   Naoe, Tomoki ^b  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; COMPLEMENTARY DNA; TRANSCRIPTION FACTOR RUNX1;

AML1 GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLAST CELL CRISIS; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CANCER INHIBITION; CELL GROWTH; CELL ISOLATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA BINDING; FLOW CYTOMETRY; GENE MUTATION; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PLASMID; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WILD TYPE;

ANIMALS; BLAST CRISIS; BLOTTING, WESTERN; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DNA MUTATIONAL ANALYSIS; DNA PRIMERS; FLOW CYTOMETRY; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MICE; MICE, INBRED C57BL; MUTATION, MISSENSE; PHENOTYPE; PLASMIDS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 84884743586     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074864     Document Type: Article

References (57)

1. Ren R, (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nature reviews 5: 172-183.
2. Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, et al. (2006) Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England journal of medicine 355: 2408-2417.
3. Perrotti D, Jamieson C, Goldman J, Skorski T, (2010) Chronic myeloid leukemia: mechanisms of blastic transformation. The Journal of clinical investigation 120: 2254-2264.
4. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, et al. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. The New England journal of medicine 344: 1038-1042.
5. Nowicki MO, Falinski R, Koptyra M, Slupianek A, Stoklosa T, et al. (2004) BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks. Blood 104: 3746-3753.
6. Ito Y, (1999) Molecular basis of tissue-specific gene expression mediated by the runt domain transcription factor PEBP2/CBF. Genes Cells 4: 685-696.
7. Blyth K, Cameron ER, Neil JC, (2005) The RUNX genes: gain or loss of function in cancer. Nature reviews 5: 376-387.
8. Speck NA, Gilliland DG, (2002) Core-binding factors in haematopoiesis and leukaemia. Nature reviews 2: 502-513.
9. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR, (1996) AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84: 321-330.
10. Rubin CM, Larson RA, Anastasi J, Winter JN, Thangavelu M, et al. (1990) t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 76: 2594-2598.
11. Osato M, (2004) Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene 23: 4284-4296.
12. Osato M, Asou N, Abdalla E, Hoshino K, Yamasaki H, et al. (1999) Biallelic and heterozygous point mutations in the runt domain of the AML1/PEBP2alphaB gene associated with myeloblastic leukemias. Blood 93: 1817-1824.
13. Watanabe-Okochi N, Kitaura J, Ono R, Harada H, Harada Y, et al. (2008) AML1 mutations induced MDS and MDS/AML in a mouse BMT model. Blood 111: 4297-4308.
14. Imai Y, Kurokawa M, Izutsu K, Hangaishi A, Takeuchi K, et al. (2000) Mutations of the AML1 gene in myelodysplastic syndrome and their functional implications in leukemogenesis. Blood 96: 3154-3160.
15. Harada H, Harada Y, Niimi H, Kyo T, Kimura A, et al. (2004) High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia. Blood 103: 2316-2324.
16. Grossmann V, Kohlmann A, Zenger M, Schindela S, Eder C, et al. (2011) A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases. Leukemia 25: 557-560.
17. Roche-Lestienne C, Deluche L, Corm S, Tigaud I, Joha S, et al. (2008) RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance. Blood 111: 3735-3741.
18. Zhao LJ, Wang YY, Li G, Ma LY, Xiong SM, et al. (2012) Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. Blood 119: 2873-2882.
19. Harada H, Harada Y, Tanaka H, Kimura A, Inaba T, (2003) Implications of somatic mutations in the AML1 gene in radiation-associated and therapy-related myelodysplastic syndrome/acute myeloid leukemia. Blood 101: 673-680.
20. Ichikawa M, Asai T, Saito T, Seo S, Yamazaki I, et al. (2004) AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nature medicine 10: 299-304.
21. Mitani K, Ogawa S, Tanaka T, Miyoshi H, Kurokawa M, et al. (1994) Generation of the AML1-EVI-1 fusion gene in the t(3;21)(q26;q22) causes blastic crisis in chronic myelocytic leukemia. The EMBO journal 13: 504-510.
22. Nucifora G, Begy CR, Kobayashi H, Roulston D, Claxton D, et al. (1994) Consistent intergenic splicing and production of multiple transcripts between AML1 at 21q22 and unrelated genes at 3q26 in (3;21)(q26;q22) translocations. Proceedings of the National Academy of Sciences of the United States of America 91: 4004-4008.
23. Tanaka T, Mitani K, Kurokawa M, Ogawa S, Tanaka K, et al. (1995) Dual functions of the AML1/Evi-1 chimeric protein in the mechanism of leukemogenesis in t(3;21) leukemias. Molecular and cellular biology 15: 2383-2392.
24. Sood R, Talwar-Trikha A, Chakrabarti SR, Nucifora G, (1999) MDS1/EVI1 enhances TGF-beta1 signaling and strengthens its growth-inhibitory effect but the leukemia-associated fusion protein AML1/MDS1/EVI1, product of the t(3;21), abrogates growth-inhibition in response to TGF-beta1. Leukemia 13: 348-357.
25. Cuenco GM, Nucifora G, Ren R, (2000) Human AML1/MDS1/EVI1 fusion protein induces an acute myelogenous leukemia (AML) in mice: a model for human AML. Proceedings of the National Academy of Sciences of the United States of America 97: 1760-1765.
26. Cuenco GM, Ren R, (2001) Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene 20: 8236-8248.
27. Miething C, Grundler R, Mugler C, Brero S, Hoepfl J, et al. (2007) Retroviral insertional mutagenesis identifies RUNX genes involved in chronic myeloid leukemia disease persistence under imatinib treatment. Proceedings of the National Academy of Sciences of the United States of America 104: 4594-4599.
28. Ogura M, Morishima Y, Ohno R, Kato Y, Hirabayashi N, et al. (1985) Establishment of a novel human megakaryoblastic leukemia cell line, MEG-01, with positive Philadelphia chromosome. Blood 66: 1384-1392.
29. Abe A, Emi N, Kato H, Adachi K, Murate T, et al. (1995) Establishment and characterization of an immature human megakaryoblastic cell line, MEG-A2. Leukemia 9: 341-349.
30. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, et al. (1998) Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 92: 3780-3792.
31. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, et al. (1995) Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic acids research 23: 2762-2769.
32. Takeda A, Goolsby C, Yaseen NR, (2006) NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. Cancer research 66: 6628-6637.
33. Hosokawa H, Kimura MY, Shinnakasu R, Suzuki A, Miki T, et al. (2006) Regulation of Th2 cell development by Polycomb group gene bmi-1 through the stabilization of GATA3. J Immunol 177: 7656-7664.
34. Nakahara F, Sakata-Yanagimoto M, Komeno Y, Kato N, Uchida T, et al. (2010) Hes1 immortalizes committed progenitors and plays a role in blast crisis transition in chronic myelogenous leukemia. Blood 115: 2872-2881.
35. Tsuzuki S, Taguchi O, Seto M, (2011) Promotion and maintenance of leukemia by ERG. Blood 117: 3858-3868.
36. Nakagawa M, Tsuzuki S, Honma K, Taguchi O, Seto M, (2011) Synergistic effect of Bcl2, Myc and Ccnd1 transforms mouse primary B cells into malignant cells. Haematologica 96: 1318-1326.
37. Hamelin V, Letourneux C, Romeo PH, Porteu F, Gaudry M, (2006) Thrombopoietin regulates IEX-1 gene expression through ERK-induced AML1 phosphorylation. Blood 107: 3106-3113.
38. Boyapati A, Ren B, Zhang DE, (2011) SERPINB13 is a novel RUNX1 target gene. Biochemical and biophysical research communications 411: 115-120.
39. Tsuzuki S, Seto M, (2012) Expansion of functionally defined mouse hematopoietic stem and progenitor cells by a short isoform of RUNX1/AML1. Blood 119: 727-735.
40. Radich JP, Dai H, Mao M, Oehler V, Schelter J, et al. (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America 103: 2794-2799.
41. Mayotte N, Roy DC, Yao J, Kroon E, Sauvageau G, (2002) Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood 100: 4177-4184.
42. Dash AB, Williams IR, Kutok JL, Tomasson MH, Anastasiadou E, et al. (2002) A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9. Proceedings of the National Academy of Sciences of the United States of America 99: 7622-7627.
43. Signer RA, Montecino-Rodriguez E, Witte ON, Dorshkind K, (2008) Aging and cancer resistance in lymphoid progenitors are linked processes conferred by p16Ink4a and Arf. Genes & development 22: 3115-3120.
44. Rizo A, Horton SJ, Olthof S, Dontje B, Ausema A, et al. (2010) BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells. Blood 116: 4621-4630.
45. Huntly BJ, Shigematsu H, Deguchi K, Lee BH, Mizuno S, et al. (2004) MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer cell 6: 587-596.
46. Makishima H, Jankowska AM, McDevitt MA, O'Keefe C, Dujardin S, et al. (2011) CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood 117: e198-206.
47. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, et al. (2010) Regulation of myeloid leukaemia by the cell-fate determinant Musashi. Nature 466: 765-768.
48. Shen Q, Liu S, Hu J, Chen S, Yang L, et al. (2012) The differential expression pattern of the BMI-1, SALL4 and ABCA3 genes in myeloid leukemia. Cancer cell international 12: 42.
49. Yanagida M, Osato M, Yamashita N, Liqun H, Jacob B, et al. (2005) Increased dosage of Runx1/AML1 acts as a positive modulator of myeloid leukemogenesis in BXH2 mice. Oncogene 24: 4477-4485.
50. Matsuura S, Komeno Y, Stevenson KE, Biggs JR, Lam K, et al. (2012) Expression of the runt homology domain of RUNX1 disrupts homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome. Blood 120: 4028-4037.
51. Tsuzuki S, Hong D, Gupta R, Matsuo K, Seto M, et al. (2007) Isoform-specific potentiation of stem and progenitor cell engraftment by AML1/RUNX1. PLoS medicine 4: e172.
52. Tanaka T, Tanaka K, Ogawa S, Kurokawa M, Mitani K, et al. (1995) An acute myeloid leukemia gene, AML1, regulates hemopoietic myeloid cell differentiation and transcriptional activation antagonistically by two alternative spliced forms. The EMBO journal 14: 341-350.
53. Cameron ER, Neil JC, (2004) The Runx genes: lineage-specific oncogenes and tumor suppressors. Oncogene 23: 4308-4314.
54. Wotton SF, Blyth K, Kilbey A, Jenkins A, Terry A, et al. (2004) RUNX1 transformation of primary embryonic fibroblasts is revealed in the absence of p53. Oncogene 23: 5476-5486.
55. Wolyniec K, Wotton S, Kilbey A, Jenkins A, Terry A, et al. (2009) RUNX1 and its fusion oncoprotein derivative, RUNX1-ETO, induce senescence-like growth arrest independently of replicative stress. Oncogene 28: 2502-2512.
56. De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, et al. (2012) The TLX1 oncogene drives aneuploidy in T cell transformation. Nature medicine 16: 1321-1327.
57. Wotton S, Stewart M, Blyth K, Vaillant F, Kilbey A, et al. (2002) Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. Cancer research 62: 7181-7185.